Cardiol Therapeutics announces ATM equity offering program
Torys acted as Canadian counsel to the Agents with a team that included Kevin Morris (corporate/securities), Frazer House and Jordan Wright (securities/life sciences).
On June 9, 2022, Cardiol Therapeutics Inc. ("Cardiol") announced that it entered into a sales agreement (the "ATM Agreement") with Canaccord Genuity LLC and Cantor Fitzgerald & Co. (the “Agents”) for an at-the-market offering program.
The ATM Agreement will allow Cardiol to offer and sell up to US$50 million of common shares of the company (the "Offered Shares") under the ATM Program. The Offered Shares may be offered and sold by the company to the public from time to time, through the sales agents. The Offered Shares sold under the ATM Program, if any, will be sold by means of ordinary brokers' transactions on the Nasdaq Capital Market or any other trading markets for the common shares in the United States at the prevailing market prices at the time of the sale. No Offered Shares will be offered or sold through the Toronto Stock Exchange or otherwise in Canada.
Further information can be found on Newsfile Corp.’s website.
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular disease.